Center-Authored Papers

Filters: Author is Hornberger, John  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
United States
Hornberger J, Lyman GH, Chien R.  2010.  Economic implications of 21-gene recurrence score assay: US multicenter experience.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(22):e382;authorreplye383.
Hornberger J, Lyman GH, Chien R, Meropol NJ.  2012.  A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 15(8):1014-21. Abstract
Treatment Outcome
Lyman GH, Cosler LE, Kuderer NM, Hornberger J.  2007.  Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.. Cancer. 109(6):1011-8. Abstract
Tamoxifen
Lyman GH, Cosler LE, Kuderer NM, Hornberger J.  2007.  Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.. Cancer. 109(6):1011-8. Abstract
RNA, Messenger
Lyman GH, Cosler LE, Kuderer NM, Hornberger J.  2007.  Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.. Cancer. 109(6):1011-8. Abstract
Reverse Transcriptase Polymerase Chain Reaction
Hornberger J, Cosler LE, Lyman GH.  2005.  Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.. The American journal of managed care. 11(5):313-24. Abstract
Lyman GH, Cosler LE, Kuderer NM, Hornberger J.  2007.  Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.. Cancer. 109(6):1011-8. Abstract
RECURRENCE
Hornberger J, Lyman GH, Chien R.  2010.  Economic implications of 21-gene recurrence score assay: US multicenter experience.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(22):e382;authorreplye383.
Receptors, Estrogen
Hornberger J, Cosler LE, Lyman GH.  2005.  Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.. The American journal of managed care. 11(5):313-24. Abstract
Quality-Adjusted Life Years
Hornberger J, Lyman GH, Chien R, Meropol NJ.  2012.  A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 15(8):1014-21. Abstract
Prognosis
Hornberger J, Lyman GH, Chien R, Meropol NJ.  2012.  A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 15(8):1014-21. Abstract
Lyman GH, Cosler LE, Kuderer NM, Hornberger J.  2007.  Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.. Cancer. 109(6):1011-8. Abstract
Neoplasm Staging
Hornberger J, Lyman GH, Chien R, Meropol NJ.  2012.  A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 15(8):1014-21. Abstract
Neoplasm Recurrence, Local
Hornberger J, Lyman GH, Chien R, Meropol NJ.  2012.  A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 15(8):1014-21. Abstract
Lyman GH, Cosler LE, Kuderer NM, Hornberger J.  2007.  Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.. Cancer. 109(6):1011-8. Abstract
Monte Carlo Method
Lyman GH, Cosler LE, Kuderer NM, Hornberger J.  2007.  Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.. Cancer. 109(6):1011-8. Abstract
Markov Chains
Hornberger J, Cosler LE, Lyman GH.  2005.  Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.. The American journal of managed care. 11(5):313-24. Abstract
Hornberger J, Lyman GH, Chien R, Meropol NJ.  2012.  A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 15(8):1014-21. Abstract
Lymph Nodes
Lyman GH, Cosler LE, Kuderer NM, Hornberger J.  2007.  Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.. Cancer. 109(6):1011-8. Abstract
Hornberger J, Cosler LE, Lyman GH.  2005.  Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.. The American journal of managed care. 11(5):313-24. Abstract
Life Expectancy
Hornberger J, Lyman GH, Chien R, Meropol NJ.  2012.  A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 15(8):1014-21. Abstract
Humans
Hornberger J, Lyman GH, Chien R, Meropol NJ.  2012.  A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 15(8):1014-21. Abstract
Lyman GH, Cosler LE, Kuderer NM, Hornberger J.  2007.  Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.. Cancer. 109(6):1011-8. Abstract
Hornberger J, Lyman GH, Chien R.  2010.  Economic implications of 21-gene recurrence score assay: US multicenter experience.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(22):e382;authorreplye383.
Hornberger J, Cosler LE, Lyman GH.  2005.  Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.. The American journal of managed care. 11(5):313-24. Abstract